<DOC>
	<DOCNO>NCT02585622</DOCNO>
	<brief_summary>The study investigate , primarily , safety , feasibility tolerability , secondarily , preliminary efficacy allogeneic bone marrow-derived Mesenchymal Stromal Cell ( MSC ) therapy ( ORBCEL-M ) study subject type 2 diabetes ( T2D ) progressive diabetic kidney disease ( DKD ) .</brief_summary>
	<brief_title>NEPHSTROM Diabetic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Male female ≥ 40 year &lt; 85 year old . ; T2D 3 year clinician mandate responsibility management patient national guideline ; Urinary albumin excretion ( UAE ) ≥ 60 µg/min ( 24 hour urine collection ) urine albumintocreatinine ratio ( UACR ) ≥ 88 mg/g ( ≥ 10 mg/mmol ) ( spot morning urine collection ) ; Estimated GFR ( eGFR ) 3050 ml/min/1.73 m^2 CKDEPI equation 2 consecutive measurement least 30 day apart within past 6 month ; A document decline eGFR ≥ 10ml/min/1.73 m^2 past 3 year document rate eGFR decline ≥ 5 ml/min/1.73 m^2 year base 3 consecutive reading least 90 day apart past 18 month ; Lack suspicion renal diagnosis DKD ; Willing able provide write informed consent . 1 . Current rest systolic BP ≥ 150 mmHg current rest diastolic BP ≥ 90 mmHg clinical setting , despite treatment 3 hypertensive agent different class ( include one diuretic ) , measure quiet environment morning medication already take ; 2 . Initiation new antihypertensive agent within past 6 month 3 . Increase dose antihypertensive agent ≥ 100 % previous dose within past 3 month Exclusion criterion related glycaemic control : 4 . Current HbA1c &gt; 75 mmol/mol ( &gt; 9 % ) 5 . Initiation new hypoglycaemic agent within past 6 month 6 . Increase dose hypoglycaemic agent ≥ 100 % previous dose within past 3 month Exclusion criterion related dyslipidaemia : 7 . Current fasting total cholesterol &gt; 7 mmol/l 8 . Current fasting total triglyceride &gt; 3.5 mmol/l 9 . Initiation new lipid lowering agent within past 6 month Other exclusion criterion : 10 . Chronic lung liver disease ; 11 . Cardiovascular event ( myocardial infarction , stroke acute limb ischemia ) within 6 month prior enrolment ; 12 . Current history within 6 month prior enrolment NYHA class III IV heart failure ; 13 . Other concomitant disease condition opinion investigator likely pose risk patient would render patient unsuitable participation could impair patient safety ability participate study , active malignancy ; 14 . Irreversible disease condition 6month mortality estimate great 50 % ; 15 . Positive screen test clinically significant antiHLA antibody . An initial antibody screen Luminex® multiantigen bead detect class I class II MHC antibody follow Luminex single antigen bead assay determine specificity antibody detect . Potential study subject positive screen clinically significant antiHLA antibody exclude eligible participate NEPHSTROM clinical study ( MFI &gt; 1500 ) ; 16 . History presence medical condition disease , opinion Investigator may place participant unacceptable risk study participation ; 17 . Childbearing potential without use effective acceptable method contraception . Women childbearing potential include study pregnancy test negative screening visit ( V1 ) baseline visit ( V2 ) agree use adequate contraception . Adequate contraception define combination least two effective method birth control , least one physical barrier ( e.g . condom hormonal contraception implant combine oral contraceptive , certain intrauterine device ) . Women consider postmenopausal childbearing potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate ) 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL surgical treatment bilateral tubal ligation , bilateral oophorectomy , hysterectomy . 18 . Pregnancy lactate ; 19 . Participation investigational medicinal product ( IMP ) trial within 30 day inclusion concurrent study ( 18 month followup ) ; 20 . Inability understand potential risk benefit study ; 21 . Legal incapacity .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetic Kidney Disease</keyword>
	<keyword>Mesenchymal Stromal Cells ( MSC )</keyword>
	<keyword>immune response</keyword>
	<keyword>allogeneic</keyword>
	<keyword>disease progression</keyword>
</DOC>